Vaccine Optimism Pushes S&P 500, Nasdaq to Fresh Intraday Highs

Travel stocks are enjoying a boost today

Deputy Editor
Aug 24, 2021 at 12:13 PM
facebook X logo linkedin


This week is so far proving to be much better than the last one, as the three major indexes look to extend yesterday's gains. The U.S. Food and Drug Administration's (FDA) approval of the Pfizer (PFE) and BioNTech (BNTX) Covid-19 vaccine has helped to abate some variant-relates fears, with travel stocks enjoying this newfound optimism. The Nasdaq Composite (IXIC) and S&P 500 Index (SPX) are sporting solid gains this afternoon, after earlier nabbing fresh intraday highs, while the Dow Jones Industrial Average (DJI) sits firmly in the black midday. 

Continue reading for more on today's market, including: 

  • Best Buy stock gets a boost from earnings beat
  • Options bulls target bouncing DiDi Global stock.  
  • Plus, CRWD options pop ahead of NDX listing; GTS soars on buyout buzz; and TBPH plummets to record low.

MMC 0824

Crowdstrike Holdings Inc (NASDAQ:CRWD) is seeing a surge of options activity today, ahead of its Nasdaq-100 Index (NDX) debut. So far, 70,000 calls and 20,000 puts have crossed the tape, with options volume running at six times what is typically seen at this point, and call volume pacing for the 99th percentile of its annual range. The weekly 8/27 270-strike call is the most popular by far, with new position being opened there. The equity is bouncing off the 100-day moving average, last seen up 8.1% at $265.81, which is just shy of its July 23 record high of $272.63. Longer term, CRWD boasts a 140.4% year-over-year lead.

CRWD mmc

Nearing the top of the New York Stock Exchange (NYSE) is Triple-S Management Corp (NYSE:GTS), up 50.3% to trade at $35.16 at last check, after news that insurance name GuideWell will acquire the managed care company for $36 per share, in a deal valued at around $900 million. The shares are now trading at their highest level since 2018, and are up 63.9% year-to-date.

Elsewhere, Theravance Biopharma Inc (NASDAQ:TBPH) is plummeting, after its experimental inflammatory bowel disease treatment, izencitinib, failed to meet the main goal of a mid-stage study. To follow, the security received a downgrade from Cowen and Company to "market perform" from "outperform," with a hefty price-target cut to $14 from $42. No fewer than five other analysts slashed their price objectives as well. The shares are down 31.3% to trade at $9.73 at last check, after earlier dropping to a record low of $9.47. Year-over-year, TBPH has shed over 48%.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI